Recent

% | $
Quotes you view appear here for quick access.

ACADIA Pharmaceuticals Inc. Message Board

  • crecy_war_knight crecy_war_knight Jul 15, 2014 10:11 AM Flag

    Welcome Mr Stephen Davis - This guy ain't no slouch.

    Mr. Davis brings over 20 years of executive-level experience in the pharmaceutical industry. He most recently served as Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., which he joined in 2013. He led core business and finance functions there and was instrumental in developing and implementing a new corporate strategy with a multi-program portfolio. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc. from 2010 to 2013, where he oversaw business functions, including finance, commercial planning, and corporate development, and played a critical role in building and growing the company. Prior to joining Ardea, Mr. Davis served in numerous executive roles at Neurogen Corporation from 1994 to 2010, including Chief Financial Officer, Chief Operating Officer, and Chief Executive Officer, completing multiple collaborations and product acquisitions with global pharmaceutical companies. Mr. Davis currently serves on the Board of Directors of Heron Therapeutics and Synageva BioPharma Corp.

    Earlier in his career, Mr. Davis practiced as a Certified Public Accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I can see the market is very excited about his hiring, down almost 4%. I guess they figure no ST buyout now.

      • 2 Replies to bioimmunomabman
      • Wrong! Janet Yellen just spoke and made a comment about biotech and social media sectors being overvalued. All all are tanking. Another day, and this announcement may have had a positive effect. Today, everyone's attention is on the selloff. Treat this a buying opportunity.

        Sentiment: Strong Buy

      • You are a real dimwit you know that...look at the biotech sector dude...MNKD MannKind Corp. -0.09 -0.90% 9.88 242.16M 3.8 11.48 - - - - 10.02 9.97 0.046 -

        GILD Gilead Sciences Inc. -0.34 -0.38% 89.51 1.53B 55.96 90.74 - - - - 83.0456 89.85 8.736 -

        CLDX Celldex Therapeutics, Inc. -0.53 -3.68% 13.87 89.11M 10.76 38.84 - - - - 15.91 14.40 3.27 -

        MYGN Myriad Genetics Inc. -1.46 -3.61% 38.95 74.50M 20.02 42.5 - - - - 36.29 40.41 9.69 -

        ACAD ACADIA Pharmaceuticals Inc. -0.59 -2.67% 21.50 73.29M 15.64 32 - - - - 22.35 22.09 3.7 -

        IBB iShares Nasdaq Biotechnology -3.85 -1.49% 254.25 0.00 187.05 275.4 - - - - 251.11 258.10 0 -

        SLV iShares Silver Trust -0.18 -0.92% 19.92 - 17.91 23.84 - - - - 19.33 20.10 - -

        CPHD Cepheid -1.19 -2.38% 48.76 68.67M 30.95 55.89 - - - - 46.77 49.95 5.07 -

        VTI Vanguard Total Stock Market ETF -0.24 -0.23% 101.99 - 84.6 103 - - - - 101.18 102.23 - 1.08

        QQQ PowerShares QQQ -0.32 -0.33% 95.52 0.00 74.2 96.13 - - - - 93.11 95.84 0 -

        GLD SPDR Gold Shares -0.91 -0.72% 124.81 - 114.46 137.55 - - - - 124.26 125.72 - -

    • rosettawest@aol.com rosettawest Jul 15, 2014 10:34 AM Flag

      I also enjoyed "Hammer of the Gods," the lurid Led Zeppelin bio he wrote in the 1980s.
      Talented guy.

 
ACAD
32.86+0.56(+1.73%)Aug 26 4:00 PMEDT